CORPORATE PROFILE

HOME > CORPORATE PROFILE > Global Activities > History

Global Activities

History

2014
  • Merged TFB, Inc. to FR.
2012
  • Relocated the head office to Shinjuku-ku, Tokyo.
2010
  • Acquired Innogenetics N.V.
  • Acquired Fujirebio Taiwan, Inc. as a 100% subsidiary company.
2009
  • Merged American Biological Technologies, Inc. to FDI.
2008
  • Acquired American Biological Technologies, Inc. (U.S.A.) as a 100% subsidiary company of FDI.
  • Acquired Advanced Life Science Institute, Inc.
  • Merged Rebio Gen, Inc. to FR.
2007
  • Entered into contract with Japan Red Cross on CL4800 (an automated chemiluminescent enzyme immunoassay analyzer) for infectious disease screening of donated blood in blood centers.
2006
  • Launched immunological fecal occult blood test system, MagStream HT.
  • Launched automated analyzer systems with high sensitivity and specific properties, TIGRIS® DTS systems for nucleic-acid amplification testing (NAT).
  • Acquired CanAg Diagnostics AB (Sweden) as a 100% subsidiary company of FDI and renamed it Fujirebio Diagnostics AB.
2005
  • Launched automated chemiluminescent enzyme immunoassay analyzer, LUMIPULSE® S.
  • Launched automated chemiluminescent enzyme immunoassay analyzer, LUMIPULSE® Presto®II.
  • Fujirebio became a holding company, Miraca Holdings Inc., as a consequence of the business integration of Fujirebio and SRL, and transferred its business to a newly established company, Fujirebio, Inc. through corporate split.
  • SRL Inc. became a wholly owned subsidiary through a stock swap.
  • Opened Shanghai Representative office in China.
2004
  • Acquired the additional shares of SRL up to 66.67% through a tender offer bit and turned SRL into a subsidiary.
  • Launched bovine spongiform encephalopathy (BSE) screening test kit, FRELISA® BSE.
2003
  • Affixed CE Marking on SFD HIV 1/2 PA.
  • Launched new influenza test kit, ESPLINE® Influenza A&B-N.
2002
  • Launched influenza test kit, ESPLINE® Influenza A&B.
  • Acquired Chugai Diagnostics Science Company, Ltd. and renamed it Rebio Gen, Inc.
2001
  • Launched diagnostic reagents for Lumipulse system, LUMIPULSE® ITgAb, and LUMIPULSE® ITPOAb.
  • Attained ISO 13485 quality assurance system, European EN46001 standard, and ISO14001 Environmental Management System (EMS).
  • Management integration of Fujirebio America, Inc (FAI) and Fujirebio Diagnostics, Inc (FDI) carried out on July 1; named the newly founded holding company Fujirebio America, Inc. (currently a consolidated company)
  • Attained ISO14001 Environmental management systems.
  • SRL shares listed on the first section of Tokyo Security Exchange
2000
  • Completed the operational handover of its pharmaceutical business to UCB Japan Co., Ltd. (a subsidiary wholly owned by UCB S.A.)
1998
  • Acquired Diagnostic Division of Centocor Diagnostics, Inc. (PA, USA) as a subsidiary wholly owned by Fujirebio America, Inc. and renamed it Fujirebio Diagnostics, Inc. (currently a consolidated company)
1997
  • Launched diagnostic test kits ESPLINE® HBsAg, and ESPLINE® HBsAb-N.
1996
  • Acquired Toray-Fuji Bionics, Inc. as wholly-owned subsidiary and renamed it TFB, Inc. (currently a consolidated company)
  • Established Fujirebio Europe B.V. in The Netherlands.
  • Attained ISO 9001 certification at Diagnostic Division.
  • Moved Corporate Headquarters to the current address, FR BLDG, 62-5, Nihonbashi-Hamacho 2-chome, Chuo-ku, Tokyo.
  • Launched automated chemiluminescent enzyme immunoassay (CLEIA) analyzer, LUMIPULSE® f(forte).
1995
  • Launched diagnostic test kit GENEDIA® HIV-1/2 mix PA.
1992
  • Launched automated chemiluminescent enzyme immunoassay (CLEIA) analyzer, LUMIPULSE® 1200.
1990
  • SRL shares listed on the second section of Tokyo Security Exchange.
1987
  • Opened European branch office in Amsterdam, Netherlands.
  • FUJIREBIO shares listed on the first section of Tokyo Stock Exchange
  • Established Fujirebio America Inc.(FAI) in NZ, USA.
  • Launched diagnostic test kit SERODIA® HIV as the first screening test for AIDS developed and manufactured in Japan.
1986
  • Launched diagnostic test kits SERODIA® ATLA, IMMUDIA® HemSp®, RAPIDIA® D dimer, and Imnoclone CA125.
1983
  • FUJIREBIO shares listed on the second section of Tokyo Stock Exchange.
  • Changed name to FUJIREBIO, Inc.
  • Launched diagnostic test kit ACE color.
1982
  • Established Toray-fuji Bionics, Inc. as joint venture in corporation with Toray Industries, Inc.
1981
  • Established Fujirebio Taiwan Inc. (currently a consolidated subsidiary) in Taipei.
1979
  • Set up HACHIOJI Plant in Hachioji-shi, Tokyo.
  • Launched diagnostic test kit SERODIA®-Anti HBs (hepatitis B)
1978
  • Set up Central Research Laboratories in Hachioji-shi, Tokyo.
  • Launched diagnostic test kit SERODIA®-TP (syphilis).
1970
  • Established Tokyo Special Reference Laboratories, Inc. (currently SRL, Inc.) as Japan's first commercial reference laboratory.
  • Launched international sales of TPHA.
1966
  • Entered the field of Clinical Diagnostics.
  • Launched Treponema pallidum hemagglutination test kit, TPHA.
1954
  • Moved into blood banking industry and started blood supply business.
1950
  • Founded and incorporated as Fujizoki Pharmaceutical Co., Ltd in Shinjuku, Tokyo for manufacturing and sale of pharmaceutical products.

PAGE TOP

Miraca Holdings
Fujirebio Inc. is a member of Miraca Group.